Teclistamab
A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
What will happen during the trial?
This is a single-arm, non-randomized, multicenter, prospective study of Teclistamab (TECVAYLI™), in adult patients with RRMM, in the post-marketing setting. Teclistamab (TECVAYLI™), the humanized IgG-4 PAA bispecific antibody, targets the CD3 receptor complex on T cells and BCMA on B-lineage cells.
This study will investigate the use of prophylactic tocilizumab to reduce the incidence and severity of CRS associated with teclistamab administration, to enable administration of the step-up dosing regimen of teclistamab in an outpatient setting.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 75 patients (estimated)
- Sponsors
- Sarah Cannon Research Institute
- Collaborators
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1746
- NCT Identifier
- NCT05972135
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.